A detailed analysis of the Lck signaling pathway may yield additional candidate molecules that can be targeted by pharmacological agents to overcome HDAC inhibitor-induced resistance in synovial sarcoma and potentially other related sarcomas. Here, HDAC9 is linked to sarcoma.